Lupin has reported results for fourth quarter and year ended March 31, 2017.
The company has reported a fall of 39.48% in its net profit after tax at Rs 549.05 crore for the quarter ended March 31, 2017 as compared to Rs 907.24 crore for the same quarter in the previous year. Total income of the company decreased by 10.14% at Rs 2965.71 crore for quarter under review as compared to Rs 3300.22 crore for the quarter ended March 31, 2016.
On consolidated basis, the company has reported a fall of 49.16% in its net profit at Rs 380.21 crore for the quarter ended March 31, 2017 as compared to Rs 747.88 crore for the same quarter in the previous year. However, total income of the company increased by 1.57% at Rs 4298.64 crore for quarter under review as compared to Rs 4232.31 crore for the same quarter ended previous year.
For the year ended March 31, 2017, the company has posted a rise of 10.97% in its net profit at Rs 3141.33 crore as compared to Rs 2830.87 crore in FY16. Total income of company increased by 11.37 % at Rs 12841.62 crore for year under review as compared to Rs 11530.62 crore for the year ended March 31, 2016.
For the year ended March 31, 2017, on the consolidated basis, the company has posted a rise of 13.12% in its net profit at Rs 2557.46 crore as compared to Rs 2260.74 crore in the previous year. Total income of the company increased by 21.88% at Rs 17600.84 crore for year under review as compared to Rs 14440.73 crore for the year ended March 31, 2016.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: